ReviewJournal of clinical medicine2015
Biomarkers of Renal Disease and Progression in Patients with Diabetes.
Review in Journal of clinical medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association of Interleukin-6 -174G/C Polymorphism with the Risk of Diabetic Nephropathy in Type 2 Diabetes: A Meta-analysis.Current medical science · 2019Pooled it
- Pooled it
- Probiotic Soy Milk Consumption and Renal Function Among Type 2 Diabetic Patients with Nephropathy: a Randomized Controlled Clinical Trial.Probiotics and antimicrobial proteins · 2019Trial
- Trial
- Individual and Combined Effects of Commercial Glyphosate and Dicamba-Based Herbicide Formulations on Cytotoxicity, Oxidative Stress and Cell Death on Human Intestinal Caco-2 Cells.Journal of xenobiotics · 2026Article
- The translational potential of m6A RNA methylation in DKD: emerging biomarkers for early detection and targeted therapies.Frontiers in medicine · 2026Review
- Comprehensive Analysis and Experimental Validation of Immune-Related Biomarkers and Immune Microenvironment in Diabetic Nephropathy.Journal of inflammation research · 2025Article
- Is the urinary neutrophil gelatinase-associated lipocalin concentration in children and adolescents with type 1 diabetes mellitus different from that in healthy children?Biochemia medica · 2024Article
- Transcriptomic analysis of diabetic kidney disease and neuropathy in mouse models of type 1 and type 2 diabetes.Disease models & mechanisms · 2023Article
- From Diabetic Nephropathy to End-Stage Renal Disease: The Effect of Chemokines on the Immune System.Journal of diabetes research · 2023Article
- Prediction of the Short-Term Risk of New-Onset Renal Dysfunction in Patients with Type 2 Diabetes: A Longitudinal Observational Study.Journal of immunology research · 2022Observational
- The Pathogenesis of End-Stage Renal Disease from the Standpoint of the Theory of General Pathological Processes of Inflammation.International journal of molecular sciences · 2021Review
- Diabetic patients with chronic kidney disease: Non-invasive assessment of cardiovascular risk.World journal of diabetes · 2021Review
- Potential Biomarkers in Diagnosis of Renal Acanthamoebiasis.International journal of molecular sciences · 2021Article
- The Role of Chemokines and Chemokine Receptors in Diabetic Nephropathy.International journal of molecular sciences · 2020Review
- Safety of Permanent Pacemaker Implantation: A Prospective Study.Journal of clinical medicine · 2019Article
- Analysis of longitudinal semicontinuous data using marginalized two-part model.Journal of translational medicine · 2018Article
- Renal fat fraction and diffusion tensor imaging in patients with early-stage diabetic nephropathy.European radiology · 2018Observational
- Soluble plasma proteins ST2 and CD163 as early biomarkers of nephropathy in Swedish patients with diabetes, 15-34 years of age: a prospective cohort study.Diabetology & metabolic syndrome · 2017Article
- Immune Cells and Inflammation in Diabetic Nephropathy.Journal of diabetes research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes prevalence is increasing worldwide, mainly due to the increase in type 2 diabetes. Diabetic nephropathy occurs in up to 40% of people with type 1 or type 2 diabetes. It is important to identify patients at risk of diabetic nephropathy and those who will progress to end stage renal disease. In clinical practice, most commonly used markers of renal disease and progression are serum creatinine, estimated glomerular filtration rate and proteinuria or albuminuria. Unfortunately, they are all insensitive. This review summarizes the evidence regarding the prognostic value and benefits of targeting some novel risk markers for development of diabetic nephropathy and its progression. It is focused mainly on tubular biomarkers (neutrophil-gelatinase associated lipocalin, kidney injury molecule 1, liver-fatty acid-binding protein, N-acetyl-beta-d-glucosaminidase), markers of inflammation (pro-inflammatory cytokines, tumour necrosis factor-α and tumour necrosis factor-α receptors, adhesion molecules, chemokines) and markers of oxidative stress. Despite the promise of some of these new biomarkers, further large, multicenter prospective studies are still needed before they can be used in everyday clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.